Forefront Analytics’s Orchard Therapeutics ORTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
– Sell
-14,183
Closed -$110K – 71
2023
Q3
$110K Buy
+14,183
New +$76.8K 0.06% 53
2023
Q2
– Sell
-14,654
Closed -$78.7K – 78
2023
Q1
$78.7K Sell
14,654
-1,835
-11% -$10K 0.04% 64
2022
Q4
$61.2K Buy
16,489
+6,485
+65% +$28.7K 0.03% 66
2022
Q3
$54K Buy
10,004
+740
+8% +$4.12K 0.03% 63
2022
Q2
$58K Sell
9,264
-710
-7% -$4.01K 0.03% 61
2022
Q1
$72K Buy
9,974
+4,717
+90% +$46.2K 0.03% 65
2021
Q4
$70K Buy
5,257
+150
+3% +$2.48K 0.02% 60
2021
Q3
$118K Buy
5,107
+3,378
+195% +$100K 0.04% 58
2021
Q2
$75K Buy
1,729
+118
+7% +$6.57K 0.03% 64
2021
Q1
$118K Sell
1,611
-1,598
-50% -$114K 0.05% 61
2020
Q4
$139K Buy
3,209
+172
+6% +$7.7K 0.06% 56
2020
Q3
$123K Buy
3,037
+1,124
+59% +$58.1K 0.06% 52
2020
Q2
$115K Buy
+1,913
New +$175K 0.07% 51

Other funds holding ORTX

Forefront Analytics's ORTX Position: Q4 2023 in Review

Forefront Analytics sold out of Orchard Therapeutics (ORTX) in Q4 2023, closing a stake of 14,183 shares — an estimated $110K sold.

Forefront Analytics first reported a position in ORTX in Q2 2020 and held it in 13 quarters. The position peaked at $139K in Q4 2020. 47 funds tracked by Wall St. Rank hold ORTX as of Q4 2023.

  • Forefront Analytics reported no remaining Orchard Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Forefront Analytics sold 14,183 Orchard Therapeutics shares in Q4 2023, an estimated $110K.
  • Forefront Analytics first reported a position in Orchard Therapeutics in Q2 2020 and held it in 13 quarters.
  • Forefront Analytics's Orchard Therapeutics position peaked at $139K in Q4 2020.
  • 47 funds tracked by Wall St. Rank held Orchard Therapeutics as of Q4 2023.

Based on Forefront Analytics's 13F filing for Q4 2023, filed 14 Feb 2024.